แก้ไข: ภาพยนตร์เรื่อง The Wolf of Wall Street จะเปิดตัวการเสนอขาย NFT ซึ่งสนับสนุนโดย Aventus

Aventus ได้ร่วมมือกับผู้ถือสิทธิ์ของ The Wolf of Wall Street เพื่อผลิตคอลเลกชันประวัติศาสตร์ของ NFT เพื่อเป็นการฉลองครบรอบ 10 ปีของภาพยนตร์

ลอนดอน , April 21, 2023 (GLOBE NEWSWIRE) — Aventus ผู้ให้บริการโซลูชัน Web3 สำหรับองค์กรต่าง ๆ ได้ร่วมมือกับผู้ถือลิขสิทธิ์ภาพยนตร์เรื่อง The Wolf of Wall Street อีกทั้งผู้ผลิตและนักตัดต่อภาพยนตร์ชั้นนำระดับโลกเพื่อสร้าง The Wolf of Wall Street Experience ซึ่งเป็นซีรีส์ของ NFT ที่จะทำหน้าที่เป็นกุญแจสำคัญในการปลดล็อกส่วนต่าง ๆ เพื่อให้มีประสบการณ์กว้างขึ้น

เนื่องจากมีรายได้จากบ็อกซ์ออฟฟิศทั่วโลกเกือบ 400 ล้านดอลลาร์ ได้รับการเสนอชื่อเข้าชิงรางวัลออสการ์ 5 รายการ ซึ่งรวมถึงสาขาภาพยนตร์ยอดเยี่ยม และได้รับการบันทึกสถิติโลกของ Guinness ในเรื่องการสบถมากที่สุดในภาพยนตร์ ผลกระทบของ The Wolf of Wall Street ต่อวัฒนธรรมประชานิยมนิยมจึงยังคงมีอยู่มาตลอดเกือบทศวรรษหลังจากออกฉาย โดยมีการใช้มีมของภาพยนตร์หลายล้านครั้งอย่างต่อเนื่อง

The Wolf of Wall Street Experience จะให้เปิดให้แฟน ๆ ของภาพยนตร์และผู้ที่ชื่นชอบ Web3 สามารถเข้าไปดูเนื้อหา รางวัล และสัมผัสประสบการณ์สุดพิเศษผ่านซีรีส์ของ NFT แบบจำกัด NFT จะมีเนื้อหาพิเศษจากภาพยนตร์เรื่องนี้ ซึ่งรวมถึงมุมใหม่ ๆ ของฉากที่โด่งดัง รวมทั้งเครื่องแต่งกายของจริงที่นักแสดงสวมใส่ อุปกรณ์ประกอบฉาก และของที่ระลึกอื่น ๆ นอกจากนี้ แฟน ๆ จะได้สัมผัสกับประสบการณ์จริงและเสมือนจริง ซึ่งรวมถึงการเฉลิมฉลองวันครบรอบสไตล์ฮอลลีวูดในเดือนธันวาคมนี้

การเปิดตัวมีกำหนดในไตรมาสที่สองของปี 2566 พร้อมสิทธิประโยชน์เพิ่มเติมสำหรับผู้เข้าร่วมชุมชนก่อนใคร สามารถดูข้อมูลเพิ่มเติมสามารถได้บนเว็บไซต์ทางการที่: www.wolfofwallstreet.io

ผู้สร้าง NFT ดังกล่าวคือเครือข่าย Aventus ที่เป็นกลางทางคาร์บอน ซึ่งเป็นเลเยอร์ 1 (พาราเชน) บน Polkadot ซึ่งหมายความว่าโปรเจกต์นี้จะใช้ประโยชน์จากระบบนิเวศของ Polkadot อย่างเต็มที่ รวมถึงความสามารถในการปรับขนาด ความเร็ว การทำงานร่วมกัน และความปลอดภัยที่เพิ่มขึ้น นอกจากนี้ ยังหมายความว่าผู้ถือ NFT จะสามารถใช้ประโยชน์จากความสามารถในการทำงานร่วมกันได้อย่างเต็มที่ในกว่า 50 บล็อกเชน รวมทั้ง Ethereum ด้วย

Alan Vey ผู้ก่อตั้งและประธานเจ้าหน้าที่บริหารของ Aventus ได้แสดงความคิดเห็นว่า “The Wolf of Wall Street เป็นหนึ่งในภาพยนตร์ที่โดดเด่นที่สุด ไม่เพียงแต่ในวัฒนธรรมสมัยนิยมในวงกว้างเท่านั้น แต่ยังเจาะจงในชุมชนบล็อกเชนด้วย เรารู้สึกตื่นเต้นที่สามารถนำภาพยนตร์เรื่องนี้มาสู่ Web3 และตื่นเต้นที่ได้เป็นส่วนหนึ่งของช่วงเวลาแห่งประวัติศาสตร์ของอุตสาหกรรม เนื่องจากบล็อกบัสเตอร์ได้กลายเป็นภาคส่วนล่าสุดที่ตระหนักถึงประโยชน์ของ NFT ในการสร้างชุมชนและการมีส่วนร่วม”

Gavin Wood ผู้ก่อตั้ง Polkadot & Ethereum กล่าวเสริมว่า “ระบบนิเวศพาราเชนของ Polkadot มีเป้าหมายที่จะช่วยให้บล็อกเชนบรรลุวัตถุประสงค์ของตน โดยเพิ่มความสามารถในการปรับขนาด ความปลอดภัย และการทำงานร่วมกัน ซึ่งการที่ได้เฝ้าดู Aventus ใช้ประโยชน์จากการสนับสนุนนี้เพื่อสร้างโปรเจกต์ที่ก้าวล้ำอย่างแท้จริงนี้นั้นถือเป็นเรื่องที่ยอดเยี่ยมอย่างมาก”

เกี่ยวกับ Aventus
Aventus นำองค์กรเข้าสู่ Web3 ซึ่งช่วยให้องค์กรสามารถสร้างกระแสรายได้ใหม่ ปรับปรุงประสิทธิภาพการดำเนินงาน และรองรับธุรกิจในอนาคตได้ ประสบการณ์รวมกันกว่าเจ็ดทศวรรษในด้าน Web3 และความเป็นผู้นำระดับองค์กรนั้นทำให้ Aventus ทำงานร่วมกับองค์กรแต่ละแห่งเพื่อกำหนดขอบเขตกรณีการใช้งานที่เป็นไปได้ และปรับแต่งผลิตภัณฑ์สไตล์ SaaS ตลอดจนบำรุงรักษาและจัดการโซลูชัน ดังนั้นองค์กรจึงสามารถมุ่งเน้นไปที่สิ่งที่ตนทำได้ดีที่สุดได้

www.aventus.io/

สื่อมวลชนสอบถามได้ที่:
Ellie Hyman
ellie.hyman@aventus.io

GlobeNewswire Distribution ID 1000805446

Beer and Beats: Victoria™ Partners with Leading Mexican Band Grupo Firme for 2023 United States Tour

Traditional Mexican beer brand offers fans the chance to connect with Grupo Firme via all-access concert trip, prize packs

Grupo Firme and Victoria

Beer and Beats: Victoria™ Partners with Leading Mexican Band Grupo Firme for 2023 United States Tour

CHICAGO, April 21, 2023 (GLOBE NEWSWIRE) — Considered Mexico’s oldest beer brand, VictoriaTM has announced a new partnership with Grupo Firme, one of the most popular acts in Latin music today. As presenting sponsor of the nationwide Hay Que Conectarla tour, Victoria is elevating the experience for Grupo Firme fans at all U.S. concerts and launching a sweepstakes to reward a lucky beer drinker with a trip for four to see the Latin stars perform live.

“Victoria is proud to bring together the authentic taste of Victoria beer with the charisma and exuberance of Grupo Firme, as both brands are deeply connected to Mexican culture,” said Ryan Anderson, Senior Director, Brand Marketing, Victoria. “Victoria is known as one of Mexico’s ‘best kept secrets,’ but this partnership allows us to expand the reach of our brand’s rich Mexican heritage to new fans through the unique sounds of Grupo Firme and a once-in-a-lifetime concert experience.”

To enter the sweepstakes, consumers 21+ can scan the QR code found on Victoria displays at retailers nationwide and complete an entry form from May 8 through August 31. One grand prize winner will receive an exclusive all-access experience, complete with soundcheck access with the band and VIP seating for the concert. In addition to the grand prize, fans can win a Victoria and Grupo Firme prize pack, including a branded jersey, a wireless speaker and more.

Founded in 2013, Grupo Firme is a Regional Mexican Band based in Tijuana, Baja California. In 2022, Grupo Firme cemented themselves as top artists in the Latin music space by selling out the most consecutive nights at the Crypto.com Arena of any Spanish-speaking act and taking home a major win at the Latin Grammys for Best Banda Album. The same year, the band made history as the first Regional Mexican Band to ever play at Coachella as a main act for both weekends and had more than 1.6 million people attend their 2022 tour.1 With a mix of original songs, covers and collaborations with popular artists, Grupo Firme has captivated new fans across the nation, selling out stadium shows, with over 21 sold-out shows from their 2022 tour alone.

“Like our fans, we take pride in our heritage and we’re honored to have Victoria, a beer with strong Mexican roots, as a partner,” said Eduin Caz, lead singer of Grupo Firme. “Victoria has a proud legacy and a long tradition of bringing people together which is exactly what we love about touring – seeing our fans dancing and singing along, and of course, enjoying authentic Mexican beer.”

Victoria is the presenting sponsor of Grupo Firme’s 2023 U.S. tour, which includes 12 upcoming appearances in 10 cities. More dates will be announced soon.

  • April 21 and 22: Fort Meyers, FL
  • April 28: Nashville, TN
  • April 29: Birmingham, AL
  • May 5: Memphis, TN
  • May 6: Oklahoma City, OK
  • May 12 and 13: El Paso, TX
  • May 19: Tucson, AZ
  • May 20: Albuquerque, NM
  • May 27: Los Angeles, CA
  • May 28: Chicago, IL

In 1865, Victoria beer was born in Toluca, Mexico and features the unique barley crop and top water quality of the area. This combination led to a historied production of some of Mexico’s leading beer in both domestic and international markets. Today, Victoria’s resiliency and popularity keep it in-market and has the honor of being the grandfather of all Mexican beer brands to date.

For more information, visit VictoriaUSA.com and @CervezaVictoriaUSA on Instagram.

NO PURCHASE NECESSARY. Open only to legal residents of the 50 U.S. and D.C., 21 or older. Instant Win Game is void in New Jersey; Sweepstakes/Instant Win Game is void where prohibited. Starts 10:00 AM ET on 5/8/23 and ends 11:59 PM ET on 8/31/23. No alcohol awarded with prizes. For complete details, see Official Rules at VictoriaUSA.com.

About Victoria™
Considered the oldest beer in Mexico, Victoria™ is an ultra-premium, Vienna-style lager with light-to-medium body and slight malt sweetness. Its flavor contains a toasted malt character perfectly balanced with a smooth crisp finish. The brand has true Mexican authenticity and a proud heritage, with a long tradition of bringing people together. For more information, follow Victoria on Facebook at Facebook.com/cervezavictoriausa. Victoria is exclusively brewed in Mexico and imported and marketed for the U.S. by Crown Imports LLC


1 Attendance numbers based on Grupo Firme’s United States, Mexico, Colombia, Coachella and Monday night tour stops in 2022.

Media Contact:
Stephanie McGuane
Stephanie.McGuane@cbrands.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bf44aa4c-1495-4401-811a-542ed843acc0

GlobeNewswire Distribution ID 8812652

Gorilla Technology Group Names New Global Head of Customer Success

Technology Leader to Drive Customer Success and Partnerships

LONDON, April 21, 2023 (GLOBE NEWSWIRE) — Gorilla Technology Group Inc. (“Gorilla”) (NASDAQ: GRRR), a global provider of AI-based edge video analytics, IoT technologies, and cybersecurity, today announced Mohan Raj Kumar has joined the company as its Global Head of Customer Success Alliance. In his new role, Kumar will engage with Gorilla customers to create exceptional success for them and ensure that they seamlessly achieve their digital transformation objectives. In addition, he will focus on driving innovation across Gorilla’s core offerings while monitoring the competitive landscape.

Kumar brings more than 27 years of experience in information communications technology and networking, helping companies innovate in this fast-evolving landscape, up and down the value chain to create compelling value propositions that best meet customer needs. He has spent a better part of 23 years as a Consultant at Cisco and Director/General Manager at HCL Technologies. Kumar holds a master’s in computer engineering from Birla Institute of Technology (BITS), Pilani, India and is currently pursuing his PhD in AI and machine learning.

“I am honoured to join the Gorilla tribe as its Global Head of Customer Success,” said Mohan. “Technology continues to shape markets, our lives, and the way we transact on an everyday basis. Technological innovation is core to businesses like Gorilla, which strives to stay ahead of its competition with a focus on providing better solutions to the customer and market they serve. I am excited to be part of a team that is 100% committed to innovation and customer success. I will be working very closely with the various facets of the business to intelligently plan actionable events and create a culture of collaboration and excellence that will allow us to thrive both as individuals and as a company. I look forward to working with the executive leadership team to deliver differentiated Security Convergence, SOC & Air Gap solutions, as we realize our ambitious plans together to innovate, scale and grow.”

“Mohan is an outstanding technology leader with a record of continuous success in the IT industry, building world-class technology teams, near and offshore centers and helping take organizations to the next level, in terms of products, platforms and services,” said Jay Chandan, Gorilla Chairman & CEO. “I am delighted to welcome Mohan to our senior management team, and I am looking forward to working alongside him, as we execute on the next chapter of our company’s future to deliver successfully for our customers worldwide.”

About Gorilla Technology Group Inc.
Gorilla, headquartered in London U.K., is a global solution provider in security intelligence, network intelligence, business intelligence and IoT technology. Gorilla develops a wide range of solutions including Smart Cities, Smart Retail, Enterprise Security, and Smart Media. In addition, Gorilla provides a complete Security Convergence Platform to government institutions, telecom companies and private enterprises with network surveillance and cyber security.

Gorilla places an emphasis on offering leading technology, expert service, and precise delivery, and ensuring top-of-the-line, intelligent and strong edge AI solutions that enable customers to improve operational performance and efficiency. With continuous core technology development, Gorilla delivers edge AI solutions to managed service providers, distributors, system integrators, and hardware manufacturers. For more information, please visit our website: Gorilla-Technology.com.

Media Contact:
Jeff Fox
The Blueshirt Group for Gorilla
+1 (415) 828-8298
jeff@blueshirtgroup.com

Investor Relations Contact:
Gary Dvorchak
The Blueshirt Group for Gorilla
+1 (323) 240-5796
gary@blueshirtgroup.com

Scott McCabe
The Blueshirt Group for Gorilla
+1 (917) 434-3275
scott@blueshirtgroup.com

GlobeNewswire Distribution ID 8812459

Intesa Sanpaolo at Salone del Mobile, supporting supply chain and sustainable lighting in design

MILAN, Italy, April 21, 2023 (GLOBE NEWSWIRE) — A total of thirty-five supply chain contracts signed, 450 suppliers involved and about 3,200 employees with a turnover of over 2 billion euros through the Supply Chain Development Programme. These are just some of the results achieved by Intesa Sanpaolo, institutional partner of the Salone del Mobile Milano 2023 – Milan Design Week – for the seventh year and Italy’s leading bank in providing financial support to the furniture and home decor sector in Italy, which hosted at the Aurore arena, the beating heart of the biennial lighting exhibition Euroluce, the talk ‘Sustainable lighting trends and prospects in design’. The meeting was attended by Italian lighting and design entrepreneurs who reflected on the sustainable development of the sector between innovation and traditions, ecological transition and the role of technology for a zero-impact future.

The economic scenario of the furniture sector was presented by Stefania Trenti, Head of the Industry Research Office at Intesa Sanpaolo. A round table discussion saw the participation of Niccolò Bacci, Head of the Fashion & Textile Desk at Intesa Sanpaolo, and entrepreneurs Roberto Beltrami, Director of Wave Murano Glass, an Italian excellence specialising in the production of artistic glass with a focus on energy recovery, and Martina Lamperti, Circular Economy Manager of Krill Design, a startup included in Intesa Sanpaolo’s Up2Stars for the Bioeconomy, which helps companies give value to organic waste from the food industry by transforming it into natural and compostable biopolymers that are used to create functional eco-design objects, including the Ohmie lamp listed in the ADI Design Index 2022.

One of the highlights was the dialogue between Paolo Melone, Head of Marketing Coordination and Business Development at Intesa Sanpaolo, Carla Morogallo, Director General of Triennale Milano, and Mara Servetto, co-founder of Migliore+Servetto, a prestigious international design studio based in Milan specialising in the creation of branding projects and narrative spaces, which has carried out more than 600 projects in 21 different countries since 1997, winning numerous international awards including three Compasso d’Oro and thirteen Red Dot Design Awards. The talk was introduced by Paolo Melone.

Furniture and lighting are among the leading Made in Italy sectors. Thanks to the strong post-Covid growth, according to estimates by Intesa Sanpaolo’s Studies and Research Department, the turnover of Italian home design has nearly reached 32 billion euros, confirming Italy’s position as the leading production hub in the European Union, ahead of Germany.

“The final figures for 2022,” Intesa Sanpaolo explains, “confirmed significant growth, with exports up 13.4% for furniture and 8.5% for equipment and lighting. Sales to the United States stand out in this regard (+24.9% for furniture and +27.7% for equipment and lighting), reaching 1.9 billion euros in 2022 (382 million euros more than in 2021).”

For more information:
Press Office LaPresse ufficio.stampa@lapresse.it

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/76322373-e2b4-4943-9298-540fe165b2e9

GlobeNewswire Distribution ID 8812772

Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch Study

  • Perioperative toripalimab plus chemotherapy significantly improved EFS and reduced risk of disease recurrence, progression events or death by 60% among resectable stage III NSCLC patients, compared to chemotherapy alone
  • Results from the Neotorch study were presented during the ASCO April Plenary Series

SHANGHAI, China, April 20, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that positive interim event-free survival (EFS) results from the Neotorch study were presented at the ASCO April Plenary Series.

Neotorch is the world’s first phase 3 registered study demonstrating that perioperative treatment with anti-PD-1 monoclonal antibody significantly extends EFS of patients with resectable non-small cell lung cancer (NSCLC). It aims to evaluate the efficacy and safety of perioperative toripalimab, Junshi Biosciences’ anti-PD-1 monoclonal antibody, in combination with chemotherapy, followed by toripalimab maintenance versus perioperative chemotherapy alone in resectable stage II/III NSCLC.

Among 404 stage lll NSCLC patients, the interim EFS analysis after a median follow-up of 18.25 months (cut-off date: Nov 30, 2022) revealed a significant EFS improvement in the toripalimab arm (HR = 0.40 [95% Cl, 0.277-0.565]; two-sided P < 0.0001). The median EFS was not reached in the toripalimab arm while it was 15.1 months in the placebo arm. Toripalimab demonstrated a consistent favorable effect on EFS in all subgroups, regardless of PD-L1 expression status.

In the toripalimab arm, the major pathological response (MPR) and pathologic complete response (pCR) rates per blinded independent pathologic review (BIPR) of the study were also higher compared to the placebo arm, with rates of 48.5% vs. 8.4% (P<0.0001) and 24.8% vs. 1.0% (P<0.0001), respectively.

Similarly, the overall survival (OS) results showed a trend favoring toripalimab. The median OS was not reached in the toripalimab arm, while it was 30.4 months in the placebo arm (HR=0.62). OS will be formally tested at the final analysis.

In addition, after neoadjuvant therapy, more patients from the toripalimab arm underwent surgery compared to the placebo arm (82.2% vs. 73.3%), 95.8% and 92.6% of the patients underwent surgery and achieved R0 resection, respectively. The treatment was well-tolerated, with no new safety signals identified.

Based on the Neotorch study, the National Medical Products Administration of China (NMPA) has accepted the supplemental new drug application (sNDA) for toripalimab in combination with chemotherapy as perioperative treatment and toripalimab monotherapy as maintenance therapy after adjuvant therapy for the treatment of resectable stage III NSCLC.

“The Neotorch study has pioneered the world’s first ‘3+1+13’ perioperative treatment model for NSCLC, which incorporates immunotherapy into both preoperative neoadjuvant and postoperative adjuvant treatments,” said Neotorch’s Principal Investigator, Professor Shun LU from the Shanghai Chest Hospital. “The study results show that the addition of toripalimab to chemotherapy provided a superior EFS in stage III NSCLC patients than chemotherapy alone, while maintaining a manageable safety profile. We are hopeful that our innovative solution will further improve the effectiveness and assessibility of lung cancer treatments and medications and ignite a new torch of hope for patients!”

Dr. Jianjun ZOU, President of Global Research and Development at Junshi Biosciences, “Lung cancer has the highest mortality rate of all malignant cancers worldwide. Even with radical surgery in the earlier stages, some patients still experience recurrence or death. Today, immunotherapy has become standard of care for various late-stage cancers, and the exploration of its potential use as early-stage treatment is showing promising results. The Neotorch study has strengthened our resolve to find a cure for more cancer patients. The NMPA is currently reviewing our sNDA for the new indication based on the Neotorch data, and we are excited to work together to benefit early-stage lung cancer patients with this innovative therapy!”

About the Neotorch Study

The Neotorch Study (NCT04158440) is a randomized, double-blind, placebo-controlled, Phase III trial evaluating the efficacy and safety of perioperative toripalimab plus chemotherapy, followed by toripalimab maintenance versus chemotherapy in resectable stage II/III NSCLC. Patients with stage II/III resectable NSCLC and without EGFR/ALK alterations for non-squamous NSCLC were randomized 1:1 to receive 240 mg toripalimab or placebo, combined with chemotherapy Q3W for 3 cycles before surgery and one cycle after surgery, followed by toripalimab or placebo monotherapy Q3W for 13 cycles. The chemotherapy backbones varied depending on the histology of the cancer, with paclitaxel or docetaxel plus platinum for squamous cell carcinoma, and pemetrexed plus platinum for non-squamous cell carcinoma. Stratification variables for randomization included disease stage, histopathologic subtype, PD-L1 expression and surgical procedure. Primary endpoints were EFS as assessed by investigator and MPR rate as assessed by BIPR in the stage III and the ITT populations. Secondary endpoints included OS, pCR rate, EFS as assessed by independent review committee (IRC), and safety.

About Toripalimab

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumor cells.

More than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). Currently, there are six approved indications for toripalimab in China:

  1. unresectable or metastatic melanoma after failure of standard systemic therapy;
  2. recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;
  3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;
  4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;
  5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”);
  6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”).

The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.

In the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).

In Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC, in December 2022 and February 2023.

About Junshi Biosciences

Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company’s continuous efforts towards innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has about 3,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

GlobeNewswire Distribution ID 8812412

Istiqlal Mosque to accommodate 250 thousand Muslims during Eid prayer

Jakarta (ANTARA) – Istiqlal Mosque in Central Jakarta is ready to accommodate up to 250 thousand Muslims, who will throng the mosque for the Eid al-Fitr prayer on Saturday (April 22), according to its Grand Imam, Nasaruddin Umar.”If needed, the Istiqlal Mosque can be prepared to accommodate 200 thousand people or, if the (outer) red-floored courtyard is opened, up to 250 thousand people,” Umar noted, as per the statement here on Friday. s the mosque is expected to be full of worshippers during Eid al-Fitr, visitors should maintain order while joining the congregation there, he emphasized. Umar, who earlier served as deputy religious affairs minister, also remarked that Vice President Ma’ruf Amin as well as several ministers, high-ranking officials, and ambassadors will offer prayer at the Istiqlal Mosque. “God Willing, visitors will throng the Istiqlal Mosque as the mosque reopens for its first public Eid al-Fitr prayer after the renovation is completed,” Umar stated. Istiqlal Mosque, being the largest in Indonesia and Southeast Asia, is operating with high service standards and emergency procedures, he affirmed. “We even have a contingency protocol in case of electric supply disruption,” the grand imam added. Meanwhile, he urged visitors planning to attend the Eid al-Fitr prayer at the mosque to adhere to health protocols, including wearing masks, while joining the congregation. “Masks are effective not only to prevent COVID-19 but also prevent other diseases,” he remarked. Umar said that Saturday’s Eid al-Fitr prayer at Istiqlal Mosque will be led by the mosque’s permanent Imam, Ahmad Muzakir, while the sermon after the prayer will be delivered by Jakarta’s Syarif Hidayatullah State Islamic University Rector Professor Saepudin Jahar. baca-jugaRelated news: Muslims should celebrate Eid al-Fitr in simplicity: MinisterRelated news: President to offer Eid al-Adha prayer at Istiqlal Mosque

Source: Antara News Agency